The hypothesis that CD4+ cell inflammation contributes to the pathology of lymphedema is supported by our previous studies demonstrating that blockade of TGF-B1 activation in the mouse tail model significantly improves lymphedema and is associated with markedly decreased tissue inflammation, CD4+ cell infiltration, and expression of Th1/Th2 markers. The gene discussed is CD4; the disease is lymphedema.